High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanoma
BACKGROUND It remains unclear whether high doses of glucocorticoids have a negative impact on the efficacy of checkpoint inhibitors. To control for the potential association between immune‐related adverse events (irAEs) and improved survival, this study examined a unique cohort of patients who had t...
Uložené v:
| Vydané v: | Cancer Ročník 124; číslo 18; s. 3706 - 3714 |
|---|---|
| Hlavní autori: | , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
Wiley Subscription Services, Inc
15.09.2018
|
| Predmet: | |
| ISSN: | 0008-543X, 1097-0142, 1097-0142 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | BACKGROUND
It remains unclear whether high doses of glucocorticoids have a negative impact on the efficacy of checkpoint inhibitors. To control for the potential association between immune‐related adverse events (irAEs) and improved survival, this study examined a unique cohort of patients who had the same irAE treated with varying glucocorticoid doses.
METHODS
In total, 98 patients with melanoma who had ipilimumab‐induced hypophysitis were identified retrospectively in the Partners Healthcare system using an automated electronic medical record query tool. Patients with melanoma who received ipilimumab at Massachusetts General Hospital without developing hypophysitis were listed in an actively maintained institutional patient database. Glucocorticoid doses for patients with hypophysitis were categorized as low dose (LD) or high dose (HD). Survival analyses were performed for patients who received ipilimumab monotherapy.
RESULTS
Both overall survival (OS) and the time to treatment failure were significantly longer in the LD group compared with the HD group (hazard ratio, 0.24; P = .002 and 0.28, P = .001, respectively). Median OS and the time to treatment failure were not reached in the LD group and were 23.3 and 14.5 months, respectively, in the HD group. All patients who had hypophysitis had improved OS compared with patients who did not have hypophysitis (median, 28.2 vs 9.5 months; P = .0003). This advantage was maintained in the HD group versus the nonhypophysitis group (P = .02). Radiologic and endocrinologic outcomes and symptom resolution did not differ in the LD group versus the HD group.
CONCLUSIONS
Among patients with melanoma who had ipilimumab‐induced hypophysitis, those who received higher doses of glucocorticoids had reduced survival. This is the first study to demonstrate a potential negative effect of high glucocorticoid doses on the efficacy of checkpoint inhibitors after an irAE. These findings have potential implications for the management of other irAEs.
This study is the first analysis of the effects of differing glucocorticoid doses on the antitumor efficacy of checkpoint inhibitors after the development of an immune‐related adverse event. The results demonstrate that high dosages of glucocorticoids may have a negative impact on the antitumor efficacy of checkpoint inhibitors and do not improve other outcomes for patients with hypophysitis. |
|---|---|
| AbstractList | It remains unclear whether high doses of glucocorticoids have a negative impact on the efficacy of checkpoint inhibitors. To control for the potential association between immune-related adverse events (irAEs) and improved survival, this study examined a unique cohort of patients who had the same irAE treated with varying glucocorticoid doses.BACKGROUNDIt remains unclear whether high doses of glucocorticoids have a negative impact on the efficacy of checkpoint inhibitors. To control for the potential association between immune-related adverse events (irAEs) and improved survival, this study examined a unique cohort of patients who had the same irAE treated with varying glucocorticoid doses.In total, 98 patients with melanoma who had ipilimumab-induced hypophysitis were identified retrospectively in the Partners Healthcare system using an automated electronic medical record query tool. Patients with melanoma who received ipilimumab at Massachusetts General Hospital without developing hypophysitis were listed in an actively maintained institutional patient database. Glucocorticoid doses for patients with hypophysitis were categorized as low dose (LD) or high dose (HD). Survival analyses were performed for patients who received ipilimumab monotherapy.METHODSIn total, 98 patients with melanoma who had ipilimumab-induced hypophysitis were identified retrospectively in the Partners Healthcare system using an automated electronic medical record query tool. Patients with melanoma who received ipilimumab at Massachusetts General Hospital without developing hypophysitis were listed in an actively maintained institutional patient database. Glucocorticoid doses for patients with hypophysitis were categorized as low dose (LD) or high dose (HD). Survival analyses were performed for patients who received ipilimumab monotherapy.Both overall survival (OS) and the time to treatment failure were significantly longer in the LD group compared with the HD group (hazard ratio, 0.24; P = .002 and 0.28, P = .001, respectively). Median OS and the time to treatment failure were not reached in the LD group and were 23.3 and 14.5 months, respectively, in the HD group. All patients who had hypophysitis had improved OS compared with patients who did not have hypophysitis (median, 28.2 vs 9.5 months; P = .0003). This advantage was maintained in the HD group versus the nonhypophysitis group (P = .02). Radiologic and endocrinologic outcomes and symptom resolution did not differ in the LD group versus the HD group.RESULTSBoth overall survival (OS) and the time to treatment failure were significantly longer in the LD group compared with the HD group (hazard ratio, 0.24; P = .002 and 0.28, P = .001, respectively). Median OS and the time to treatment failure were not reached in the LD group and were 23.3 and 14.5 months, respectively, in the HD group. All patients who had hypophysitis had improved OS compared with patients who did not have hypophysitis (median, 28.2 vs 9.5 months; P = .0003). This advantage was maintained in the HD group versus the nonhypophysitis group (P = .02). Radiologic and endocrinologic outcomes and symptom resolution did not differ in the LD group versus the HD group.Among patients with melanoma who had ipilimumab-induced hypophysitis, those who received higher doses of glucocorticoids had reduced survival. This is the first study to demonstrate a potential negative effect of high glucocorticoid doses on the efficacy of checkpoint inhibitors after an irAE. These findings have potential implications for the management of other irAEs.CONCLUSIONSAmong patients with melanoma who had ipilimumab-induced hypophysitis, those who received higher doses of glucocorticoids had reduced survival. This is the first study to demonstrate a potential negative effect of high glucocorticoid doses on the efficacy of checkpoint inhibitors after an irAE. These findings have potential implications for the management of other irAEs. It remains unclear whether high doses of glucocorticoids have a negative impact on the efficacy of checkpoint inhibitors. To control for the potential association between immune-related adverse events (irAEs) and improved survival, this study examined a unique cohort of patients who had the same irAE treated with varying glucocorticoid doses. In total, 98 patients with melanoma who had ipilimumab-induced hypophysitis were identified retrospectively in the Partners Healthcare system using an automated electronic medical record query tool. Patients with melanoma who received ipilimumab at Massachusetts General Hospital without developing hypophysitis were listed in an actively maintained institutional patient database. Glucocorticoid doses for patients with hypophysitis were categorized as low dose (LD) or high dose (HD). Survival analyses were performed for patients who received ipilimumab monotherapy. Both overall survival (OS) and the time to treatment failure were significantly longer in the LD group compared with the HD group (hazard ratio, 0.24; P = .002 and 0.28, P = .001, respectively). Median OS and the time to treatment failure were not reached in the LD group and were 23.3 and 14.5 months, respectively, in the HD group. All patients who had hypophysitis had improved OS compared with patients who did not have hypophysitis (median, 28.2 vs 9.5 months; P = .0003). This advantage was maintained in the HD group versus the nonhypophysitis group (P = .02). Radiologic and endocrinologic outcomes and symptom resolution did not differ in the LD group versus the HD group. Among patients with melanoma who had ipilimumab-induced hypophysitis, those who received higher doses of glucocorticoids had reduced survival. This is the first study to demonstrate a potential negative effect of high glucocorticoid doses on the efficacy of checkpoint inhibitors after an irAE. These findings have potential implications for the management of other irAEs. BACKGROUND It remains unclear whether high doses of glucocorticoids have a negative impact on the efficacy of checkpoint inhibitors. To control for the potential association between immune‐related adverse events (irAEs) and improved survival, this study examined a unique cohort of patients who had the same irAE treated with varying glucocorticoid doses. METHODS In total, 98 patients with melanoma who had ipilimumab‐induced hypophysitis were identified retrospectively in the Partners Healthcare system using an automated electronic medical record query tool. Patients with melanoma who received ipilimumab at Massachusetts General Hospital without developing hypophysitis were listed in an actively maintained institutional patient database. Glucocorticoid doses for patients with hypophysitis were categorized as low dose (LD) or high dose (HD). Survival analyses were performed for patients who received ipilimumab monotherapy. RESULTS Both overall survival (OS) and the time to treatment failure were significantly longer in the LD group compared with the HD group (hazard ratio, 0.24; P = .002 and 0.28, P = .001, respectively). Median OS and the time to treatment failure were not reached in the LD group and were 23.3 and 14.5 months, respectively, in the HD group. All patients who had hypophysitis had improved OS compared with patients who did not have hypophysitis (median, 28.2 vs 9.5 months; P = .0003). This advantage was maintained in the HD group versus the nonhypophysitis group (P = .02). Radiologic and endocrinologic outcomes and symptom resolution did not differ in the LD group versus the HD group. CONCLUSIONS Among patients with melanoma who had ipilimumab‐induced hypophysitis, those who received higher doses of glucocorticoids had reduced survival. This is the first study to demonstrate a potential negative effect of high glucocorticoid doses on the efficacy of checkpoint inhibitors after an irAE. These findings have potential implications for the management of other irAEs. This study is the first analysis of the effects of differing glucocorticoid doses on the antitumor efficacy of checkpoint inhibitors after the development of an immune‐related adverse event. The results demonstrate that high dosages of glucocorticoids may have a negative impact on the antitumor efficacy of checkpoint inhibitors and do not improve other outcomes for patients with hypophysitis. BACKGROUNDIt remains unclear whether high doses of glucocorticoids have a negative impact on the efficacy of checkpoint inhibitors. To control for the potential association between immune‐related adverse events (irAEs) and improved survival, this study examined a unique cohort of patients who had the same irAE treated with varying glucocorticoid doses.METHODSIn total, 98 patients with melanoma who had ipilimumab‐induced hypophysitis were identified retrospectively in the Partners Healthcare system using an automated electronic medical record query tool. Patients with melanoma who received ipilimumab at Massachusetts General Hospital without developing hypophysitis were listed in an actively maintained institutional patient database. Glucocorticoid doses for patients with hypophysitis were categorized as low dose (LD) or high dose (HD). Survival analyses were performed for patients who received ipilimumab monotherapy.RESULTSBoth overall survival (OS) and the time to treatment failure were significantly longer in the LD group compared with the HD group (hazard ratio, 0.24; P = .002 and 0.28, P = .001, respectively). Median OS and the time to treatment failure were not reached in the LD group and were 23.3 and 14.5 months, respectively, in the HD group. All patients who had hypophysitis had improved OS compared with patients who did not have hypophysitis (median, 28.2 vs 9.5 months; P = .0003). This advantage was maintained in the HD group versus the nonhypophysitis group (P = .02). Radiologic and endocrinologic outcomes and symptom resolution did not differ in the LD group versus the HD group.CONCLUSIONSAmong patients with melanoma who had ipilimumab‐induced hypophysitis, those who received higher doses of glucocorticoids had reduced survival. This is the first study to demonstrate a potential negative effect of high glucocorticoid doses on the efficacy of checkpoint inhibitors after an irAE. These findings have potential implications for the management of other irAEs. This study is the first analysis of the effects of differing glucocorticoid doses on the antitumor efficacy of checkpoint inhibitors after the development of an immune‐related adverse event. The results demonstrate that high dosages of glucocorticoids may have a negative impact on the antitumor efficacy of checkpoint inhibitors and do not improve other outcomes for patients with hypophysitis. |
| Author | Sullivan, Ryan J. Freedman, Christine Faje, Alexander T. Rubin, Krista Cohen, Justine Lawrence, Donald Flaherty, Keith Fadden, Riley |
| Author_xml | – sequence: 1 givenname: Alexander T. orcidid: 0000-0002-4092-5409 surname: Faje fullname: Faje, Alexander T. email: afaje@partners.org organization: Neuroendocrine Unit, Massachusetts General Hospital – sequence: 2 givenname: Donald surname: Lawrence fullname: Lawrence, Donald organization: Center for Melanoma, Massachusetts General Hospital Cancer Center – sequence: 3 givenname: Keith surname: Flaherty fullname: Flaherty, Keith organization: Center for Melanoma, Massachusetts General Hospital Cancer Center – sequence: 4 givenname: Christine surname: Freedman fullname: Freedman, Christine organization: Center for Melanoma, Massachusetts General Hospital Cancer Center – sequence: 5 givenname: Riley surname: Fadden fullname: Fadden, Riley organization: Center for Melanoma, Massachusetts General Hospital Cancer Center – sequence: 6 givenname: Krista surname: Rubin fullname: Rubin, Krista organization: Center for Melanoma, Massachusetts General Hospital Cancer Center – sequence: 7 givenname: Justine surname: Cohen fullname: Cohen, Justine organization: Neuroendocrine Unit, Massachusetts General Hospital – sequence: 8 givenname: Ryan J. surname: Sullivan fullname: Sullivan, Ryan J. organization: Center for Melanoma, Massachusetts General Hospital Cancer Center |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29975414$$D View this record in MEDLINE/PubMed |
| BookMark | eNp90dFq1jAUB_AgG-7b9MYHkIA3InRLmjZtLuVjOmE4GArelSQ9Xc9om5qkG9-dj7Bn9EmWrdOLIUIghPz-h8M5h2RvchMQ8oazY85YfmIn648Fl7l6QTacqSpjvMj3yIYxVmdlIX4ckMMQrtOzykvxkhzkSlVlwYsNuTvDq_73r7vWBaBXw2KddT6iddgG2jlPYw80etBxhClS11GcccBxGbVJMZzaxUJL-93s5n4XMGKg6egQnEUd09ctxp56WF1Y_A3e6IHiRGcdMdUMqxhh0JMb9Suy3-khwOun-4h8_3T6bXuWnV98_rL9eJ5ZoYTKurbudG2sBSFbWxtjSlGXtVVWahCmMwaqQnAoi6I1iUlpWyUsSNBdIWQujsj7te7s3c8FQmxGDBaG1AW4JTQ5k0UlleBlou-e0Wu3-Cl11-Q8r5QUsmJJvX1SixmhbWaPo_a75s-sE_iwAutdCB66v4Sz5mGRzcMim8dFJsyeYYsxDcxN0Wsc_h3ha-QWB9j9p3iz_bq9XDP3sdK3Dg |
| CitedBy_id | crossref_primary_10_1186_s12967_023_04329_7 crossref_primary_10_1080_2162402X_2023_2261264 crossref_primary_10_59578_jmsni_2025_16_1_1_7 crossref_primary_10_1016_j_immuni_2020_08_005 crossref_primary_10_1016_j_jaad_2020_04_174 crossref_primary_10_1016_j_it_2021_02_006 crossref_primary_10_1080_17446651_2019_1701434 crossref_primary_10_1158_2326_6066_CIR_23_0498 crossref_primary_10_2147_JBM_S468921 crossref_primary_10_3389_fendo_2023_1268402 crossref_primary_10_4049_jimmunol_1900264 crossref_primary_10_1136_bmj_m736 crossref_primary_10_14341_omet12828 crossref_primary_10_1007_s11936_023_01024_0 crossref_primary_10_3389_fimmu_2021_793831 crossref_primary_10_3389_fphar_2022_820724 crossref_primary_10_1172_jci_insight_188843 crossref_primary_10_3390_cancers16010101 crossref_primary_10_1016_j_jdcr_2020_04_010 crossref_primary_10_1016_j_semnephrol_2023_151346 crossref_primary_10_1016_j_biomaterials_2025_123419 crossref_primary_10_3389_fmed_2022_898790 crossref_primary_10_1155_2019_4836404 crossref_primary_10_1177_2050313X231195462 crossref_primary_10_2217_imt_2019_0132 crossref_primary_10_3238_PersDia_2025_06_27_01 crossref_primary_10_1136_jitc_2023_007324 crossref_primary_10_3389_fimmu_2023_1176370 crossref_primary_10_1136_jcp_2023_209173 crossref_primary_10_1136_jitc_2022_005646 crossref_primary_10_1158_2326_6066_CIR_18_0487 crossref_primary_10_1172_JCI176567 crossref_primary_10_1016_j_iac_2021_12_006 crossref_primary_10_1136_rmdopen_2024_004308 crossref_primary_10_4103_ds_DS_D_24_00059 crossref_primary_10_1177_1758835920980546 crossref_primary_10_1007_s13671_023_00395_8 crossref_primary_10_1111_imr_13262 crossref_primary_10_3390_cells11050770 crossref_primary_10_58931_crt_2024_1147 crossref_primary_10_2337_dc22_2202 crossref_primary_10_1007_s00520_023_08132_4 crossref_primary_10_1186_s12967_024_05063_4 crossref_primary_10_1080_07853890_2025_2453829 crossref_primary_10_1182_blood_2020009016 crossref_primary_10_7326_AITC202402200 crossref_primary_10_1016_j_smim_2021_101473 crossref_primary_10_1097_MED_0000000000000664 crossref_primary_10_1097_BOR_0000000000000701 crossref_primary_10_1007_s00432_023_04659_5 crossref_primary_10_1111_imr_13257 crossref_primary_10_1146_annurev_pharmtox_022820_093805 crossref_primary_10_1097_IN9_0000000000000012 crossref_primary_10_1002_acr2_11181 crossref_primary_10_1007_s11894_022_00852_7 crossref_primary_10_7759_cureus_30638 crossref_primary_10_1007_s11926_018_0770_0 crossref_primary_10_1111_imr_13250 crossref_primary_10_1016_j_biomaterials_2020_120407 crossref_primary_10_1080_1744666X_2020_1804362 crossref_primary_10_1016_j_gie_2024_01_024 crossref_primary_10_3389_fimmu_2023_1258873 crossref_primary_10_1007_s12094_020_02397_5 crossref_primary_10_1016_j_autrev_2020_102595 crossref_primary_10_1080_08923973_2025_2542134 crossref_primary_10_1146_annurev_cancerbio_030518_055552 crossref_primary_10_1038_s41467_023_41798_2 crossref_primary_10_1007_s11102_019_00978_4 crossref_primary_10_1136_jitc_2021_002535 crossref_primary_10_1007_s11894_020_0752_z crossref_primary_10_1136_jitc_2023_006814 crossref_primary_10_1016_j_oraloncology_2024_107161 crossref_primary_10_1111_bcp_14433 crossref_primary_10_1111_imr_13249 crossref_primary_10_4049_jimmunol_1801533 crossref_primary_10_1007_s00262_021_02955_y crossref_primary_10_1097_MED_0000000000000652 crossref_primary_10_2217_fon_2019_0101 crossref_primary_10_1002_cncr_33436 crossref_primary_10_1111_imj_14992 crossref_primary_10_1093_oncolo_oyae361 crossref_primary_10_1136_jitc_2020_001818 crossref_primary_10_1016_j_tem_2021_10_009 crossref_primary_10_1038_s41584_021_00584_4 crossref_primary_10_1172_JCI131194 crossref_primary_10_1038_s41591_024_02895_x crossref_primary_10_1038_s41574_021_00484_3 crossref_primary_10_1136_jitc_2021_003277 crossref_primary_10_1097_RHU_0000000000001199 crossref_primary_10_1016_j_jaip_2020_06_028 crossref_primary_10_1038_s41467_024_46195_x crossref_primary_10_1136_jitc_2021_002742 crossref_primary_10_1038_s41571_022_00600_w crossref_primary_10_1136_jitc_2021_002627 crossref_primary_10_2147_CMAR_S224791 crossref_primary_10_1080_1750743X_2025_2473305 crossref_primary_10_1136_jim_2021_002099 crossref_primary_10_1016_j_biopha_2022_112687 crossref_primary_10_1016_j_ejca_2021_07_023 crossref_primary_10_1136_annrheumdis_2019_216510 crossref_primary_10_1136_jitc_2023_007195 crossref_primary_10_1016_j_xkme_2021_08_008 crossref_primary_10_1634_theoncologist_2018_0764 crossref_primary_10_3390_cancers17010076 crossref_primary_10_1002_ana_25708 crossref_primary_10_1016_j_ejca_2020_09_032 crossref_primary_10_1186_s12902_022_01151_y crossref_primary_10_1007_s00520_022_07233_w crossref_primary_10_1158_1078_0432_CCR_20_2291 crossref_primary_10_1080_14737140_2020_1803742 crossref_primary_10_1111_cei_13424 crossref_primary_10_3389_fonc_2024_1510278 crossref_primary_10_3389_fonc_2021_633032 crossref_primary_10_1210_jendso_bvad002 crossref_primary_10_1158_1078_0432_CCR_21_1240 crossref_primary_10_3389_fonc_2022_961266 crossref_primary_10_1634_theoncologist_2018_0883 crossref_primary_10_1016_j_cotox_2022_100362 crossref_primary_10_1634_theoncologist_2019_0129 crossref_primary_10_3390_jpm13030415 crossref_primary_10_1016_j_jdcr_2019_07_015 crossref_primary_10_1136_jitc_2021_003965 crossref_primary_10_1002_cncr_32966 crossref_primary_10_1016_S1470_2045_20_30107_8 crossref_primary_10_1186_s13046_021_01919_5 crossref_primary_10_3389_fonc_2024_1436996 crossref_primary_10_1007_s11912_020_0897_9 crossref_primary_10_1016_S1155_1941_24_46684_5 crossref_primary_10_1007_s00262_021_02855_1 crossref_primary_10_1016_j_ccell_2025_01_004 crossref_primary_10_1016_j_ejca_2020_09_022 crossref_primary_10_1212_NXI_0000000000000967 crossref_primary_10_1016_j_beha_2025_101625 crossref_primary_10_1016_j_eprac_2022_04_010 crossref_primary_10_1177_2042018819896182 crossref_primary_10_1212_CON_0000000000000807 crossref_primary_10_1002_mdr2_70019 crossref_primary_10_1146_annurev_med_050219_034237 crossref_primary_10_1007_s00262_021_03115_y crossref_primary_10_1158_2326_6066_CIR_20_0372 crossref_primary_10_1080_2162402X_2025_2543510 crossref_primary_10_1111_imj_16629 crossref_primary_10_1136_jitc_2022_005635 crossref_primary_10_1097_CMR_0000000000001035 crossref_primary_10_1111_bju_16121 crossref_primary_10_1111_apt_17980 crossref_primary_10_1002_cncr_31627 crossref_primary_10_3389_fonc_2022_847917 crossref_primary_10_1016_j_beem_2019_04_010 crossref_primary_10_1111_his_13963 crossref_primary_10_1111_bjd_19313 crossref_primary_10_1016_j_autrev_2019_102456 crossref_primary_10_1016_j_urolonc_2025_02_017 crossref_primary_10_1200_JCO_18_02141 crossref_primary_10_1038_s41571_025_01026_w crossref_primary_10_1002_acr2_70002 crossref_primary_10_1016_j_det_2024_02_012 crossref_primary_10_1001_jamadermatol_2022_0354 crossref_primary_10_1016_j_jfma_2022_03_017 crossref_primary_10_1158_1078_0432_CCR_24_2990 crossref_primary_10_1093_oncolo_oyac252 crossref_primary_10_3322_caac_21596 crossref_primary_10_1136_jitc_2022_006398 crossref_primary_10_1111_dth_14618 crossref_primary_10_1210_endocr_bqae084 crossref_primary_10_1007_s11892_021_01435_y crossref_primary_10_1016_j_tranon_2023_101787 crossref_primary_10_1097_CCO_0000000000000635 crossref_primary_10_1016_j_jaad_2019_09_026 crossref_primary_10_1097_PAS_0000000000001730 crossref_primary_10_1111_bjd_19322 crossref_primary_10_1007_s00520_023_08083_w crossref_primary_10_1080_07853890_2021_1931956 crossref_primary_10_2147_CMAR_S444916 crossref_primary_10_1007_s00415_024_12660_2 crossref_primary_10_1111_cen_15240 crossref_primary_10_1016_S2468_1253_20_30014_5 crossref_primary_10_1080_1750743X_2025_2492541 crossref_primary_10_1016_j_coi_2021_02_002 crossref_primary_10_1158_2326_6066_CIR_22_0362 crossref_primary_10_7759_cureus_82701 crossref_primary_10_1007_s10147_023_02349_3 crossref_primary_10_1016_j_jbspin_2024_105795 crossref_primary_10_1007_s40674_019_00131_z crossref_primary_10_1016_j_cell_2020_06_001 crossref_primary_10_1136_jitc_2020_001329 crossref_primary_10_3390_cancers12030546 crossref_primary_10_1186_s12967_020_02627_y crossref_primary_10_1210_clinem_dgab672 crossref_primary_10_1016_j_immuni_2023_01_022 crossref_primary_10_1001_jama_2020_17308 crossref_primary_10_1212_CON_0000000000001359 crossref_primary_10_1136_jitc_2024_009051 crossref_primary_10_1136_jitc_2022_005490 crossref_primary_10_1136_jitc_2025_011545 crossref_primary_10_3390_cells14181450 crossref_primary_10_1001_jamadermatol_2021_0727 crossref_primary_10_1016_j_intimp_2021_108031 crossref_primary_10_1177_09733698241276714 crossref_primary_10_1146_annurev_pathol_042020_042741 crossref_primary_10_1158_1078_0432_CCR_21_1283 crossref_primary_10_1177_10932607241301699 crossref_primary_10_1002_ijc_34940 crossref_primary_10_1200_EDBK_321059 crossref_primary_10_1016_j_beem_2022_101668 crossref_primary_10_1111_bju_16310 crossref_primary_10_1002_cam4_2397 crossref_primary_10_1016_j_tem_2019_06_004 crossref_primary_10_1016_j_cllc_2021_02_017 crossref_primary_10_1161_JAHA_120_018306 crossref_primary_10_1038_s41379_020_00653_1 crossref_primary_10_1097_RHU_0000000000001209 crossref_primary_10_1111_imj_70183 crossref_primary_10_2147_JIR_S282600 crossref_primary_10_3389_fimmu_2022_804597 crossref_primary_10_3390_cancers14041057 crossref_primary_10_1016_j_jtho_2021_06_024 crossref_primary_10_1016_S1470_2045_21_00305_3 crossref_primary_10_1038_s41574_024_01077_6 crossref_primary_10_1093_oncolo_oyac220 crossref_primary_10_1007_s40278_018_55344_0 crossref_primary_10_3390_cancers14215451 crossref_primary_10_1001_jamanetworkopen_2023_40695 crossref_primary_10_1016_j_eprac_2024_03_023 crossref_primary_10_1093_oncolo_oyac108 crossref_primary_10_3389_fphar_2023_1078338 crossref_primary_10_1136_bcr_2022_252766 crossref_primary_10_1186_s40425_019_0756_0 crossref_primary_10_1016_j_rdc_2024_02_007 crossref_primary_10_1002_cncr_31789 crossref_primary_10_1080_14712598_2021_1869211 crossref_primary_10_1111_phpp_12892 crossref_primary_10_1002_cncr_31786 crossref_primary_10_3389_fimmu_2022_907591 crossref_primary_10_3390_medicina61010123 crossref_primary_10_3389_fendo_2021_764138 crossref_primary_10_4251_wjgo_v15_i2_352 crossref_primary_10_1136_jitc_2024_010638 crossref_primary_10_1016_j_berh_2020_101511 crossref_primary_10_1038_s41698_023_00380_1 crossref_primary_10_1136_jitc_2021_002493 crossref_primary_10_1186_s40425_019_0820_9 crossref_primary_10_1038_s41582_024_01001_6 crossref_primary_10_1111_apt_15998 crossref_primary_10_1016_j_ando_2023_03_014 crossref_primary_10_3390_cancers17030436 crossref_primary_10_1007_s11255_023_03635_9 crossref_primary_10_1007_s00520_020_05581_z crossref_primary_10_1210_clinem_dgaf122 crossref_primary_10_1007_s40257_024_00866_z crossref_primary_10_1016_j_jaad_2020_05_045 crossref_primary_10_1186_s40425_019_0805_8 crossref_primary_10_2217_imt_2018_0146 crossref_primary_10_1007_s00432_023_05093_3 crossref_primary_10_1158_1078_0432_CCR_22_3181 crossref_primary_10_3390_ph16111610 crossref_primary_10_1016_j_phrs_2021_105997 crossref_primary_10_1002_rcr2_730 crossref_primary_10_2217_imt_2021_0061 crossref_primary_10_1016_j_berh_2022_101805 crossref_primary_10_1007_s12032_020_01357_x crossref_primary_10_1016_S1470_2045_24_00278_X crossref_primary_10_3390_clinpract13010003 crossref_primary_10_7861_clinmed_2022_0429 crossref_primary_10_2215_CJN_00990119 crossref_primary_10_1530_EJE_22_0689 crossref_primary_10_1111_imr_13239 crossref_primary_10_1016_j_mpmed_2025_07_009 crossref_primary_10_3389_fmed_2023_1213889 crossref_primary_10_3389_fonc_2022_976224 crossref_primary_10_1080_17446651_2019_1598260 crossref_primary_10_1111_cen_15075 crossref_primary_10_1007_s00520_020_05709_1 crossref_primary_10_3389_fimmu_2023_1122430 crossref_primary_10_1136_jitc_2020_002292 crossref_primary_10_1016_j_eprac_2022_06_009 crossref_primary_10_1007_s11684_019_0735_3 crossref_primary_10_1161_CIRCULATIONAHA_120_049981 crossref_primary_10_1080_1744666X_2024_2323966 crossref_primary_10_1016_j_jemermed_2021_02_020 crossref_primary_10_1186_s40842_018_0073_4 crossref_primary_10_1186_s40425_019_0729_3 crossref_primary_10_1016_j_intimp_2022_108738 crossref_primary_10_1136_bcr_2023_256675 crossref_primary_10_1634_theoncologist_2018_0359 crossref_primary_10_1007_s00262_021_02875_x crossref_primary_10_1007_s00432_022_04115_w crossref_primary_10_1111_1759_7714_13347 crossref_primary_10_1111_1759_7714_13463 crossref_primary_10_1016_j_jaad_2020_09_054 crossref_primary_10_1136_jitc_2021_002567 crossref_primary_10_1186_s40425_019_0524_1 crossref_primary_10_1016_j_jaad_2020_03_029 crossref_primary_10_1016_j_jhep_2019_09_025 crossref_primary_10_3390_ijms24032769 crossref_primary_10_1097_RHU_0000000000001370 crossref_primary_10_1016_j_mcna_2020_09_009 crossref_primary_10_1136_jitc_2020_000779 crossref_primary_10_1002_ccr3_2027 crossref_primary_10_1002_jgh3_12554 crossref_primary_10_1016_j_cell_2021_02_011 crossref_primary_10_1016_j_jaccao_2020_11_012 crossref_primary_10_1016_j_rdc_2022_02_002 crossref_primary_10_1111_jdv_20809 crossref_primary_10_3390_jpm13081210 crossref_primary_10_1016_j_intimp_2020_106427 crossref_primary_10_1016_j_critrevonc_2025_104627 crossref_primary_10_1542_peds_2021_053363 crossref_primary_10_1080_07435800_2020_1817064 crossref_primary_10_3390_cancers16101892 crossref_primary_10_3390_jcm12103468 crossref_primary_10_1002_jvc2_27 crossref_primary_10_1016_j_jep_2024_118955 crossref_primary_10_1097_DER_0000000000000776 crossref_primary_10_1097_HEP_0000000000000045 crossref_primary_10_3389_fimmu_2021_800879 crossref_primary_10_1038_s41467_022_29539_3 crossref_primary_10_1002_ajh_25448 crossref_primary_10_3389_fimmu_2024_1499478 crossref_primary_10_3390_cancers15164176 crossref_primary_10_3389_fonc_2023_1124730 crossref_primary_10_3390_biomedicines10061334 crossref_primary_10_1136_jitc_2023_008591 crossref_primary_10_1016_j_beem_2019_101371 crossref_primary_10_1016_j_jaad_2020_03_132 crossref_primary_10_1002_eji_70033 crossref_primary_10_3389_fonc_2022_836859 crossref_primary_10_1002_cncr_32542 crossref_primary_10_1136_jitc_2019_000451 crossref_primary_10_1186_s12916_020_01549_2 crossref_primary_10_1038_s41571_020_0352_8 |
| Cites_doi | 10.1007/BF00318578 10.1016/j.ajpath.2016.08.020 10.1038/s41467-017-01062-w 10.1016/j.cell.2016.08.069 10.1200/JCO.2008.16.1927 10.1158/2326-6066.CIR-14-0217 10.1016/j.ctrv.2015.03.011 10.1158/1078-0432.CCR-07-0187 10.1158/1078-0432.CCR-14-2353 10.1007/s11102-015-0671-4 10.1016/S1359-6101(01)00038-7 10.1080/02688690120057664 10.1111/j.1399-0039.2006.00599.x 10.3171/jns.2004.101.2.0262 10.1097/00006123-199704000-00010 10.1073/pnas.160099797 10.1186/s40842-016-0034-8 10.1186/1479-5876-12-116 10.1210/jc.2014-2306 10.4049/jimmunol.170.9.4833 10.1200/JCO.2015.66.1389 10.1200/JCO.2005.04.5716 10.1080/08830180902978120 10.1056/NEJMoa1604958 10.1001/jamaoncol.2017.3064 10.1007/s11102-014-0622-5 10.1200/JCO.2015.60.8448 10.1002/cncr.24951 10.1080/2162402X.2015.1046028 |
| ContentType | Journal Article |
| Copyright | 2018 American Cancer Society 2018 American Cancer Society. |
| Copyright_xml | – notice: 2018 American Cancer Society – notice: 2018 American Cancer Society. |
| DBID | AAYXX CITATION NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 |
| DOI | 10.1002/cncr.31629 |
| DatabaseName | CrossRef PubMed Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed AIDS and Cancer Research Abstracts CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1097-0142 |
| EndPage | 3714 |
| ExternalDocumentID | 29975414 10_1002_cncr_31629 CNCR31629 |
| Genre | article Journal Article |
| GroupedDBID | --- -~X .3N .GA 05W 0R~ 10A 1CY 1L6 1OC 24P 29B 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 6J9 6P2 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AARRQ AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABHFT ABIJN ABIVO ABJNI ABLJU ABOCM ABPPZ ABPVW ABQWH ABXGK ACAHQ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACNCT ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEIGN AEIMD AENEX AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AIACR AIAGR AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EJD EMOBN EX3 F00 F01 F04 F5P FD6 FUBAC G-S G.N GNP GODZA GX1 H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M JPC KBYEO KQQ KZ1 L7B LATKE LAW LC2 LC3 LH4 LITHE LMP LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 QRW R.K ROL RWI RX1 RYL SJN SUPJJ TEORI UDS UHB V2E V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WJL WOHZO WQJ WRC WVDHM WXI WXSBR XG1 XPP XV2 Z0Y ZGI ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGXDD AGYGG AIDQK AIDYY CITATION O8X NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 |
| ID | FETCH-LOGICAL-c3939-fd8fa8bcce36dc8bbb53858c9c6ae3bfbbe7431e544dbbcc66cd93ce6eaf43623 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 372 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000449045100012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0008-543X 1097-0142 |
| IngestDate | Sat Sep 27 18:49:08 EDT 2025 Tue Oct 07 07:08:37 EDT 2025 Wed Feb 19 02:33:38 EST 2025 Sat Nov 29 07:01:59 EST 2025 Tue Nov 18 21:49:58 EST 2025 Wed Jan 22 16:39:51 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 18 |
| Keywords | melanoma hypophysitis glucocorticoids checkpoint inhibitors ipilimumab |
| Language | English |
| License | 2018 American Cancer Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3939-fd8fa8bcce36dc8bbb53858c9c6ae3bfbbe7431e544dbbcc66cd93ce6eaf43623 |
| Notes | 3636–8 See related editorial on pages this issue. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-4092-5409 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.31629 |
| PMID | 29975414 |
| PQID | 2127963670 |
| PQPubID | 2045183 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_2064769315 proquest_journals_2127963670 pubmed_primary_29975414 crossref_primary_10_1002_cncr_31629 crossref_citationtrail_10_1002_cncr_31629 wiley_primary_10_1002_cncr_31629_CNCR31629 |
| PublicationCentury | 2000 |
| PublicationDate | September 15, 2018 |
| PublicationDateYYYYMMDD | 2018-09-15 |
| PublicationDate_xml | – month: 09 year: 2018 text: September 15, 2018 day: 15 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Atlanta |
| PublicationTitle | Cancer |
| PublicationTitleAlternate | Cancer |
| PublicationYear | 2018 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2004; 101 2017; 8 1997; 40 2015; 18 1995; 90 2016; 19 2015; 3 2002; 13 2015; 33 2016; 167 2003; 170 2007; 13 2016; 186 2009; 28 2015; 28 2016; 2 2018; 4 2006; 68 2006; 24 2010; 116 2015; 41 2017; 35 2000; 97 2015; 21 2008; 26 2016; 375 2001; 15 2014; 12 2014; 99 e_1_2_8_28_1 e_1_2_8_29_1 e_1_2_8_24_1 e_1_2_8_25_1 e_1_2_8_26_1 e_1_2_8_27_1 e_1_2_8_3_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_20_1 e_1_2_8_21_1 e_1_2_8_22_1 e_1_2_8_23_1 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_14_1 e_1_2_8_15_1 e_1_2_8_16_1 e_1_2_8_10_1 e_1_2_8_11_1 e_1_2_8_12_1 e_1_2_8_30_1 29975416 - Cancer. 2018 Sep 15;124(18):3638-3640 30351493 - Cancer. 2018 Dec 15;124(24):4732 30351448 - Cancer. 2018 Dec 15;124(24):4731 |
| References_xml | – volume: 26 start-page: 5950 year: 2008 end-page: 5956 article-title: Phase I/II study of ipilimumab for patients with metastatic melanoma publication-title: J Clin Oncol – volume: 13 start-page: 95 year: 2002 end-page: 109 article-title: The roles of INF gamma in protection against tumor development and cancer immunoediting publication-title: Cytokine Growth Factor Rev – volume: 186 start-page: 3225 year: 2016 end-page: 3235 article-title: Hypophysitis secondary to cytotoxic T‐lymphocyte‐associated protein 4 blockade: insights into pathogenesis from an autopsy series publication-title: Am J Pathol – volume: 90 start-page: 637 year: 1995 end-page: 644 article-title: Hypophysitis in surgical and autoptical specimens publication-title: Acta Neuropathol – volume: 13 start-page: 6681 issue: 22 pt 1 year: 2007 end-page: 6688 article-title: Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL‐associated antigen‐4 blockade publication-title: Clin Cancer Res – volume: 15 start-page: 242 year: 2001 end-page: 245 article-title: Lymphocytic and granulocytic hypophysitis: a single centre experience publication-title: Br J Neurosurg – volume: 2 start-page: 15 year: 2016 article-title: Hypophysitis: evaluation and management [serial online] publication-title: Clin Diabetes Endocrinol – volume: 33 start-page: 3193 year: 2015 end-page: 3198 article-title: Immune‐related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center publication-title: J Clin Oncol – volume: 24 start-page: 2283 year: 2006 end-page: 2289 article-title: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T‐lymphocyte‐associated antigen 4 publication-title: J Clin Oncol – volume: 28 start-page: e1046028 year: 2015 article-title: A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab [serial online] publication-title: Oncoimmunology. – volume: 28 start-page: 239 year: 2009 end-page: 260 article-title: Molecular mechanisms of INF‐gamma to up‐regulate MHC class I antigen processing and presentation publication-title: Int Rev Immunol – volume: 41 start-page: 503 year: 2015 end-page: 510 article-title: The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant publication-title: Cancer Treat Rev – volume: 167 start-page: 397 year: 2016 end-page: 404 article-title: Loss of INF‐γ pathway genes in tumor cells as a mechanism of resistance to anti‐CTLA‐4 therapy publication-title: Cell – volume: 40 start-page: 713 year: 1997 end-page: 722 article-title: Lymphocytic and granulomatous hypophysitis: experience with 9 cases publication-title: Neurosurgery – volume: 35 start-page: 785 year: 2017 end-page: 792 article-title: Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma publication-title: J Clin Oncol – volume: 19 start-page: 82 year: 2016 end-page: 92 article-title: Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights publication-title: Pituitary – volume: 99 start-page: 4078 year: 2014 end-page: 4085 article-title: Ipilimumab‐induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma publication-title: J Clin Endocrinol Metab – volume: 21 start-page: 749 year: 2015 end-page: 755 article-title: Systemic high‐dose corticosteroid treatment does not improve the outcome of ipilimumab‐related hypophysitis: a retrospective cohort study publication-title: Clin Cancer Res – volume: 18 start-page: 630 year: 2015 end-page: 641 article-title: Hypophysitis: a single‐center case series publication-title: Pituitary. – volume: 68 start-page: 1 year: 2006 end-page: 12 article-title: Glucocorticoid modulation of cytokine signaling publication-title: Tissue Antigens – volume: 3 start-page: 464 year: 2015 end-page: 469 article-title: Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long‐term ipilimumab survivors at a single referral center publication-title: Cancer Immunol Res – volume: 101 start-page: 262 year: 2004 end-page: 271 article-title: Primary hypophysitis: a single‐center experience in 16 cases publication-title: J Neurosurg. – volume: 170 start-page: 4833 year: 2003 end-page: 4839 article-title: Inhibition of INF‐gamma signaling by glucocorticoids publication-title: J Immunol – volume: 375 start-page: 819 year: 2016 end-page: 829 article-title: Mutations associated with acquired resistance to PD‐1 blockade in melanoma publication-title: N Engl J Med – volume: 4 start-page: 173 year: 2018 end-page: 182 article-title: Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta‐analysis publication-title: JAMA Oncol – volume: 12 start-page: 116 year: 2014 article-title: Clinical experience with ipilimumab 3 mg/kg: real‐world efficacy and safety data from an expanded access program cohort [serial online] publication-title: J Transl Med – volume: 116 start-page: 1767 year: 2010 end-page: 1775 article-title: Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival publication-title: Cancer – volume: 8 start-page: 1136 year: 2017 article-title: Resistance to checkpoint blockade therapy through inactivation of antigen presentation [serial online] publication-title: Nat Commun – volume: 97 start-page: 9573 year: 2000 end-page: 9578 article-title: Inhibition of IL‐2‐induced Jak‐STAT signaling by glucocorticoids publication-title: Proc Natl Acad Sci U S A – ident: e_1_2_8_4_1 doi: 10.1007/BF00318578 – ident: e_1_2_8_30_1 doi: 10.1016/j.ajpath.2016.08.020 – ident: e_1_2_8_11_1 doi: 10.1038/s41467-017-01062-w – ident: e_1_2_8_13_1 doi: 10.1016/j.cell.2016.08.069 – ident: e_1_2_8_19_1 doi: 10.1200/JCO.2008.16.1927 – ident: e_1_2_8_24_1 doi: 10.1158/2326-6066.CIR-14-0217 – ident: e_1_2_8_27_1 doi: 10.1016/j.ctrv.2015.03.011 – ident: e_1_2_8_17_1 doi: 10.1158/1078-0432.CCR-07-0187 – ident: e_1_2_8_25_1 doi: 10.1158/1078-0432.CCR-14-2353 – ident: e_1_2_8_8_1 doi: 10.1007/s11102-015-0671-4 – ident: e_1_2_8_28_1 doi: 10.1016/S1359-6101(01)00038-7 – ident: e_1_2_8_3_1 doi: 10.1080/02688690120057664 – ident: e_1_2_8_16_1 doi: 10.1111/j.1399-0039.2006.00599.x – ident: e_1_2_8_5_1 doi: 10.3171/jns.2004.101.2.0262 – ident: e_1_2_8_6_1 doi: 10.1097/00006123-199704000-00010 – ident: e_1_2_8_15_1 doi: 10.1073/pnas.160099797 – ident: e_1_2_8_10_1 doi: 10.1186/s40842-016-0034-8 – ident: e_1_2_8_23_1 doi: 10.1186/1479-5876-12-116 – ident: e_1_2_8_7_1 doi: 10.1210/jc.2014-2306 – ident: e_1_2_8_14_1 doi: 10.4049/jimmunol.170.9.4833 – ident: e_1_2_8_21_1 doi: 10.1200/JCO.2015.66.1389 – ident: e_1_2_8_18_1 doi: 10.1200/JCO.2005.04.5716 – ident: e_1_2_8_29_1 doi: 10.1080/08830180902978120 – ident: e_1_2_8_12_1 doi: 10.1056/NEJMoa1604958 – ident: e_1_2_8_9_1 doi: 10.1001/jamaoncol.2017.3064 – ident: e_1_2_8_2_1 doi: 10.1007/s11102-014-0622-5 – ident: e_1_2_8_22_1 doi: 10.1200/JCO.2015.60.8448 – ident: e_1_2_8_20_1 doi: 10.1002/cncr.24951 – ident: e_1_2_8_26_1 doi: 10.1080/2162402X.2015.1046028 – reference: 30351448 - Cancer. 2018 Dec 15;124(24):4731 – reference: 30351493 - Cancer. 2018 Dec 15;124(24):4732 – reference: 29975416 - Cancer. 2018 Sep 15;124(18):3638-3640 |
| SSID | ssj0007253 |
| Score | 2.6816213 |
| Snippet | BACKGROUND
It remains unclear whether high doses of glucocorticoids have a negative impact on the efficacy of checkpoint inhibitors. To control for the... This study is the first analysis of the effects of differing glucocorticoid doses on the antitumor efficacy of checkpoint inhibitors after the development of... It remains unclear whether high doses of glucocorticoids have a negative impact on the efficacy of checkpoint inhibitors. To control for the potential... BACKGROUNDIt remains unclear whether high doses of glucocorticoids have a negative impact on the efficacy of checkpoint inhibitors. To control for the... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 3706 |
| SubjectTerms | checkpoint inhibitors Electronic health records Electronic medical records Glucocorticoids Health care hypophysitis Immune checkpoint Immunotherapy Inhibitors ipilimumab Melanoma Monoclonal antibodies Oncology Patients Survival |
| Title | High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanoma |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcncr.31629 https://www.ncbi.nlm.nih.gov/pubmed/29975414 https://www.proquest.com/docview/2127963670 https://www.proquest.com/docview/2064769315 |
| Volume | 124 |
| WOSCitedRecordID | wos000449045100012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1097-0142 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0007253 issn: 0008-543X databaseCode: WIN dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1097-0142 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0007253 issn: 0008-543X databaseCode: DRFUL dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bi9QwFD7szor44v1SXZeIviiUbZs2TcAXGR0UdJDFxXkruZUtzLTDdEfwzZ-wv9Ff4kma6bIoggh9aMkXUnLOSc5JTr4AvKiV4_UuVVxYUcd5qkwsSpnGhiUmzxJhlFX-solyPueLhfi8B693Z2EGfohxwc1Zhh-vnYFL1R9fkobqVm8w4mSZ2IeDDBW3mMDB25PZ6cdxJC6zwEKZ8LjI6WKkJ82OL2tfnZB-8zKvOq1-1pnd-r__vQ03g7dJ3gzqcQf2bHsXrn8K--n34MKlefz8cWG63hKfvY7BKGK7xvQE3VmC7iEZc9FJV5Nm3Syb1XYlFVbDeB41w5Cz7-vOL5GcNz3BRwaZY5Fb5yUbO-D6LQ5MqNqkaUkgdO0HxMouZdut5H04nb37Mn0fhzsaYk0FFXFteC250tpSZjRXShVuq1ELzaSlqlbKOh_FFnluFMIY00ZQbZmVdY6TJ30Ak7Zr7SMgGMkKJWtjeCpzKahibpOSJ1aLTGW8juDlTlCVDgTm7h6NZTVQL2eV6-LKd3EEz0fseqDt-CPqcCfvKphuXznKexyVWJlE8GwsRqNzOymytd0WMe6ILhM0LSJ4OOjJ2AzO76W7Wz2CV14d_tJ-NZ1PT_zb438BP4Eb6Lb5rJW0OITJ-WZrn8I1_Q2FvDmC_XLBj4Ip4NfXD_NffuIUMQ |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ba9RAFD5oFfXFuzVadURfLIQmmWSSeZTF0mIbRCruW5grBnaTZdMt-OZP6G_0l3hmMk0piiBCHgI5w4Q595kz3wF4a6XD9S5lXBhu4zyVOualSGPNEp1nCdfSSN9soqzraj7nn0JtjrsLM-JDTBtuTjO8vXYK7jak9y5RQ1Wn1physoxfhxs5Rhquc8PXw3oyxGUWQCiTKi5yOp_QSbO9y7FX_dFvQebVmNU7nf17__m79-FuiDbJ-1E8HsA10z2EW8fhPP0RnLsyj58_znU_GOKr1zEZRdq-1QPBcJZgeEimWnTSW9Ku2kW73CyFxGGYz6NkaPLt-6r3WySn7UDwEYHn-Mnt85K1GemGDRomFG3SdiQAug4jxdIsRNcvxWP4sv_hZHYQhx4NsaKc8tjqyopKKmUo06qSUhbuqFFxxYSh0kppXIxiijzXEskYU5pTZZgRNkfnSZ_AVtd35ikQzGS5FFbrKhW54FQyd0hZJUbxTGaVjeDdBacaFQDMXR-NRTNCL2eNW-LGL3EEbyba1Qjb8UeqnQuGN0F1h8ZB3qNVYmUSwevpMyqdO0kRnek3SOOu6DJO0yKC7VFQpmnQv5eut3oEu14e_jJ_M6tnn_3bs38hfgW3D06Oj5qjw_rjc7iDIZyvYEmLHdg6XW_MC7ipzpDh65deH34BkhAU_A |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ba9RAFD7oVoov3rXRqiP6ohCaZJJJ5lG2Lop1KcXCvoW5YmA3WTbdgm_-hP5Gf4lnJtOUoggi5CGQM0yYc505Z74D8MZKh-tdyrgw3MZ5KnXMS5HGmiU6zxKupZG-2UQ5n1eLBT8OtTnuLsyADzEeuDnN8PbaKbhZa3twhRqqWrXBLSfL-E3YyV0XmQnsHJ7MTo9GU1xmAYYyqeIip4sRnzQ7uBp93SP9FmZej1q925nd_c8fvgd3QrxJ3g8Cch9umPYB7H4JGfWHcOEKPX7-uNBdb4ivX8ftKNJ2je4JBrQEA0QyVqOTzpJm3Syb1XYlJA7DHT3Khibfvq87f0hy1vQEHxG4jp_cSS_ZmIGu36JpQuEmTUsCpGs_UKzMUrTdSjyC09mHr9OPcejSECvKKY-trqyopFKGMq0qKWXhko2KKyYMlVZK46IUU-S5lkjGmNKcKsOMsDm6T_oYJm3Xmj0guJflUlitq1TkglPJXJqySozimcwqG8HbS07VKkCYu04ay3oAX85qt8S1X-IIXo-06wG4449U-5cMr4Py9rUDvUe7xMokglfjZ1Q7l0sRrem2SOMu6TJO0yKCJ4OgjNOghy9dd_UI3nl5-Mv89XQ-PfFvT_-F-CXsHh_O6qNP88_P4DbGcL6EJS32YXK22ZrncEudI783L4JC_AJVehWl |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=High%E2%80%90dose+glucocorticoids+for+the+treatment+of+ipilimumab%E2%80%90induced+hypophysitis+is+associated+with+reduced+survival+in+patients+with+melanoma&rft.jtitle=Cancer&rft.au=Faje%2C+Alexander+T.&rft.au=Lawrence%2C+Donald&rft.au=Flaherty%2C+Keith&rft.au=Freedman%2C+Christine&rft.date=2018-09-15&rft.issn=0008-543X&rft.eissn=1097-0142&rft.volume=124&rft.issue=18&rft.spage=3706&rft.epage=3714&rft_id=info:doi/10.1002%2Fcncr.31629&rft.externalDBID=10.1002%252Fcncr.31629&rft.externalDocID=CNCR31629 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon |